Pro­QR spot­lights the most en­cour­ag­ing re­sults from a mixed snap­shot of ef­fi­ca­cy for cys­tic fi­bro­sis

Ex­ecs at Pro­QR Ther­a­peu­tics $PRQR are do­ing their lev­el best this af­ter­noon to ac­cen­tu­ate the pos­i­tive in their ear­ly snap­shot of the im­pact its lead RNA ther­a­py has on cys­tic fi­bro­sis. The big ques­tion is whether they can get in­vestors to look past a slate of failed p-val­ues in the Phase Ib — as well as the im­pli­ca­tions of some heavy­weight com­pe­ti­tion — as they line up reg­u­la­to­ry in­sights for the next big clin­i­cal de­vel­op­ment step.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.